Page last updated: 2024-08-26

3,7-dihydroxy-12-oxocholanoic acid and Alloxan Diabetes

3,7-dihydroxy-12-oxocholanoic acid has been researched along with Alloxan Diabetes in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Al-Salami, H; Golocorbin-Kon, S; Grujic-Letic, N; Mikov, M; Mooranian, A; Raškovic, A; Stilinovic, N; Teofilovic, B1
Al-Salami, H; Butt, G; Golocorbin-Kon, S; Mikov, M; Tucker, I1

Other Studies

2 other study(ies) available for 3,7-dihydroxy-12-oxocholanoic acid and Alloxan Diabetes

ArticleYear
Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study.
    Scientific reports, 2021, 11-11, Volume: 11, Issue:1

    Topics: Alloxan; Animals; Blood Glucose; Chenodeoxycholic Acid; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Lipids; Male; Microvessels; Ocimum basilicum; Plant Extracts; Rats; Rats, Wistar

2021
Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
    European journal of drug metabolism and pharmacokinetics, 2012, Volume: 37, Issue:2

    Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Chenodeoxycholic Acid; Cholic Acids; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Food-Drug Interactions; Gliclazide; Hypoglycemic Agents; Injections, Intravenous; Male; Probiotics; Random Allocation; Rats; Rats, Wistar

2012